Skip to main content

Table 3 Comparison of trough serum infliximab (IFX), C-reactive protein (CRP) levels, partial Mayo Score and subscores in subgroups of patients with ulcerative colitis at week 14 following the initiation of IFX infusion

From: C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study

Variable IFX responders (n = 29) IFX partial-responders (n = 24) IFX non-responders (n = 10a) P1 Value P2 Value
Trough IFX (μg/mL) 12.4 [3.2–22.4] 9.1 [3.9–13.9] 17.6 [4.9–28.8] 0.8851 0.7274
CRP (mg/dL) 0.04 [0.01–0.07] 0.56 [0.27–0.96] 0.11 [0.02–0.50] 0.0009 0.01911
Partial Mayo Score (0–9) 0 [0–1] 4 [4–6] 6.5 [5.5–7.3] <0.0001 <0.0001
Stool frequency (0–3) 0 [0–0] 2 [2–3] 3 [2–3] <0.0001 <0.0001
Rectal bleeding (0–3) 0 [0–0] 1 [1–2] 2 [2–2.5] <0.0001 <0.0001
PGA (0–3) 0 [0–0] 1 [1–1] 2 [1.5-2] <0.0001 <0.0001
  1. Data are presented as the median [interquartile range] values and compared by Wilcoxon-Mann–Whitney test. P1, responder vs partial-responder; P2, responder vs non-responder
  2. PGA Physician’s global assessment
  3. a Only 10 of 19 patients were available for evaluation at week 14 visit, the other 9 had withdrawn due to worsened UC